PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...
BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) had its price target lifted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on ...
PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in immunotherapies for cancer care, announced today its plans to conduct ...
Shares of BriaCell Therapeutics were trading at all-time lows in Monday's after-hours market, following news the company plans to sell shares in a best-efforts public offering.
Detailed price information for Briacell Therapeutics Corp (BCT-T) from The Globe and Mail including charting and trades.
Investing.com -- BriaCell Therapeutics Corp. (NASDAQ: BCTX ...
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS ...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” ...
费城和不列颠哥伦比亚省温哥华讯 - 专注于癌症免疫疗法的临床阶段生物技术公司BriaCell Therapeutics Corp.今日宣布计划进行普通股的尽力公开发售。该公司目前市值为250万美元，EBITDA为-422万美元，正积极寻求加强其财务状况。此次发售的完成和具体条款将取决于市场条件，目前尚无法确定发售是否能够完成及其具体细节。
Therapeutics trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback